Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Asset Writedowns and Impairment (2016 - 2021)

Altimmune (ALT) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $3.3 million as the latest value for Q4 2021.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $3.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $11.4 million, a N/A change, with the full-year FY2023 number at $12.4 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was $3.3 million for Q4 2021 at Altimmune, up from $30000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $24.5 million in Q4 2018 to a low of $30000.0 in Q3 2021.
  • A 3-year average of $6.2 million and a median of $2.2 million in 2019 define the central range for Asset Writedowns and Impairment.